GH Stock Price, Chart, Stats & News
GH chart
Fundamentals
Gross margin | 64.46% |
Operating margin | -44.53% |
Pretax margin | -42.52% |
Net margin | -42.39% |
Effective tax rate | 0.30% |
ROA | -20.67% |
ROE | 164.85% |
D/E | -16.94x |
Interest coverage ratio | -112.20x |
GH valuation
P/E | – |
P/S | 11.30x |
P/B | -109.62x |
P/CF | -63.12x |
P/FCF | -50.27x |
P/OCF | -63.12x |
PEG | 8.39x |
EV multiple | -26.19x |
About
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
Similar securities
Based on sector and market capitalization
